Clinical Trials

Sponsor: Adlai Nortye Biopharma Co., Ltd.

Sponsor Study ID: AN2025H0301

Study Title: The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT Number: NCT04338399

Phase: III

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Larynx, Lip, Oral Cavity and Pharynx

Study Objectives: The BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC) that have progressed after prior platinum-based therapy with or without prior anti PD 1/anti PD L1 therapy.

For more information about the trial above please contact the study team:

Principal Investigator, John Kaczmar, at kaczmar@musc.edu, or please call +1 843-792-6691.
Study Coordinator, Nikki Hill, at hilllau@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)